AstraZeneca & Regeneron to develop small molecule obesity treatment
pharmafile | July 28, 2021 | News story | Manufacturing and Production, Research and Development |
AstraZeneca and Regeneron have announced a collaboration to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
Under the collaboration both companies will equally split the R&D costs as well as any future potential profits.
The new GPR75 target was identified through the sequencing of nearly 650,000 people and identifying individuals with rare protective mutations. Individuals with at least one inactive copy of the GPR75 gene had lower body mass index (BMI) and, on average, tended to weigh about 12 pounds less and faced a 54% lower risk of obesity than those without the mutation.
Strong associations were also seen with improvements in diabetes parameters, including glucose lowering. Obesity and insulin resistance are key drivers in the development of type-2 diabetes and often lead to cardiorenal complications, as well as liver disease.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders.
“Obesity and insulin resistance remain key drivers in the development of type-2 diabetes and areas of significant unmet medical need.”
Obesity is associated with many serious health complications and drives organ dysfunction, including in the heart, liver, kidneys and pancreas. Worldwide the prevalence of obesity has more than tripled since 1975 and approximately 650 million adults are estimated to live with obesity today.
George D Yancopoulos, President and Chief Scientific Officer of Regeneron, said: “The next era of drug development is being fuelled by important genetic findings that direct drug developers on how to deploy our toolkit of biologics, small molecules and gene editing technologies.
“As experts on genetics and human biology, Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca, as we seek to develop new medicines tackling the harmful and costly obesity epidemic.”
Kat Jenkins
